Table 1. Baseline Clinical Characteristics of Patients With Siewert Type II AEG.
| Variables | Before PSM, N (%) |
After PSM, N (%) |
||||
|---|---|---|---|---|---|---|
| Married | Unmarried | P | Married | Unmarried | P | |
| N | 1149 | 474 | 474 | 474 | ||
| Age | 0.025 | 0.22 | ||||
| ≤ 56 | 296 (25.8%) | 148 (31.2%) | 135 (28.5%) | 148 (31.2%) | ||
| 56 - 75 | 725 (63.1%) | 265 (55.9%) | 290 (61.2%) | 265 (55.9%) | ||
| > 75 | 128 (11.1%) | 61 (12.9%) | 49 (10.3%) | 61 (12.9%) | ||
| Sex | < 0.001 | 0.04 | ||||
| Male | 981 (85.4%) | 347 (73.2%) | 375 (79.1%) | 347 (73.2%) | ||
| Female | 168 (14.6%) | 127 (26.8%) | 99 (20.9%) | 127 (26.8%) | ||
| Race | < 0.001 | < 0.001 | ||||
| White | 1003 (85.4%) | 404 (85.2%) | 404 (85.2%) | 404 (85.2%) | ||
| Black | 41 (3.6%) | 39 (8.2%) | 12 (2.5%) | 39 (8.2%) | ||
| Other | 105 (9.1%) | 31 (6.5%) | 58 (12.2%) | 31 (6.5%) | ||
| Grade | 0.882 | 0.462 | ||||
| G1 | 69 (6.0%) | 33 (7.0%) | 22 (4.6%) | 33 (7.0%) | ||
| G2 | 436 (37.9%) | 177 (37.3%) | 178 (37.6%) | 177 (37.3%) | ||
| G3 | 624 (54.3%) | 257 (54.2%) | 265 (55.9%) | 257 (54.2%) | ||
| G4 | 20 (1.7%) | 7 (1.5%) | 9 (1.9%) | 7 (1.5%) | ||
| Stage | 0.088 | 0.105 | ||||
| I | 234 (20.4%) | 85 (17.9%) | 93 (19.6%) | 85 (17.9%) | ||
| II | 285 (24.8%) | 142 (30.0%) | 113 (23.8%) | 142 (30.0%) | ||
| III | 630 (54.8%) | 247 (52.1%) | 268 (56.5%) | 247 (52.1%) | ||
| T stage | 0.232 | 0.228 | ||||
| T1 | 229 (19.9%) | 95 (20.0%) | 83 (17.5%) | 95 (20.0%) | ||
| T2 | 179 (15.6%) | 58 (12.2%) | 79 (16.7%) | 58 (12.2%) | ||
| T3 | 680 (59.2%) | 288 (60.8%) | 283 (59.7%) | 288 (60.8%) | ||
| T4 | 61 (5.3%) | 33 (7.0%) | 29 (6.1%) | 33 (7.0%) | ||
| N stage | 0.077 | 0.076 | ||||
| N0 | 428 (37.2%) | 191 (40.3%) | 174 (36.7%) | 191 (40.3%) | ||
| N1 | 399 (34.7%) | 143 (30.2%) | 174 (36.7%) | 143 (30.2%) | ||
| N2 | 205 (17.8%) | 76 (16.0%) | 80 (16.9%) | 76 (16.0%) | ||
| N3 | 117 (10.2%) | 64 (13.5%) | 46 (9.7%) | 64 (13.5%) | ||
| RLN | 0.911 | 0.799 | ||||
| ≤ 10 | 294 (25.6%) | 120 (25.3%) | 117 (24.7%) | 120 (25.3%) | ||
| 10 - 16 | 308 (26.8%) | 132 (27.8%) | 125 (26.4%) | 132 (27.8%) | ||
| > 16 | 547 (47.6%) | 222 (46.8%) | 232 (48.9%) | 222 (46.8%) | ||
| LNR | 0.118 | 0.177 | ||||
| ≤ 4.2 | 619 (53.9%) | 258 (54.4%) | 264 (55.7%) | 258 (54.4%) | ||
| 4.2 - 16.7 | 245 (21.3%) | 82 (17.3%) | 98 (20.7%) | 82 (17.3%) | ||
| > 16.7 | 285 (24.8%) | 134 (28.3%) | 112 (23.6%) | 134 (28.3%) | ||
| Tumor size | 0.338 | 0.966 | ||||
| ≤ 19 | 207 (15.6%) | 74 (15.6%) | 73 (15.4%) | 74 (15.6%) | ||
| 19 - 44 | 522 (45.4%) | 211 (44.5%) | 215 (45.4%) | 211 (44.5%) | ||
| > 44 | 420 (36.6%) | 189 (39.9%) | 186 (39.2%) | 189 (39.9%) | ||
| Chemotherapy | 0.148 | 0.042 | ||||
| Yes | 840 (73.1%) | 329 (69.4%) | 358 (75.5%) | 329 (69.4%) | ||
| No | 309 (26.9%) | 145 (30.6%) | 116 (24.5%) | 145 (30.6%) | ||
| Radiotherapy | 0.325 | 0.064 | ||||
| Yes | 677 (58.9%) | 266 (56.1%) | 295 (62.2%) | 266 (56.1%) | ||
| No | 472 (41.1%) | 208 (43.9%) | 179 (37.8%) | 208 (43.9%) | ||
| Dead | < 0.001 | < 0.001 | ||||
| Alive | 516 (44.9%) | 170 (35.9%) | 213 (44.9%) | 170 (35.9%) | ||
| AEG | 547 (47.6%) | 247 (52.1%) | 228 (48.1%) | 247 (52.1%) | ||
| Cardiovascular | 33 (2.9%) | 26 (5.5%) | 8 (1.7%) | 26 (5.5%) | ||
| Other | 53 (4.6%) | 31 (6.5%) | 25 (5.3%) | 31 (6.5%) | ||
AEG: adenocarcinoma of the esophagogatric junction; LNR: lymph node metastasis ratio; PSM: propensity score matching; RLN: number of removed lymph nodes.